(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.37%) $78.40
(1.35%) $2.17
(0.10%) $2 311.00
(0.41%) $26.80
(0.18%) $967.00
(-0.35%) $0.929
(-1.19%) $10.86
(-0.11%) $0.797
(0.52%) $91.61
2 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 18.00%
4.50% $ 1.160
@ $1.110
Wydano: 14 vas. 2024 @ 16:32
Zwrot: 4.50%
Poprzedni sygnał: vas. 13 - 16:30
Poprzedni sygnał:
Zwrot: 2.30 %
Live Chart Being Loaded With Signals
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease...
Stats | |
---|---|
Dzisiejszy wolumen | 4.46M |
Średni wolumen | 4.42M |
Kapitalizacja rynkowa | 175.17M |
EPS | $0 ( 2024-03-05 ) |
Następna data zysków | ( $0 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.300 |
ATR14 | $0.00700 (0.61%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Graves Kurt | Buy | 60 000 | Stock Option (right to buy) |
2024-04-04 | Kender Richard N | Buy | 60 000 | Stock Option (right to buy) |
2024-04-04 | Biondi Paul | Buy | 60 000 | Stock Option (Right to Buy) |
2024-04-04 | Fraser Claire | Buy | 60 000 | Stock Option (right to buy |
2024-04-04 | Dere Willard H | Buy | 60 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
92.36 |
Last 99 transactions |
Buy: 7 007 921 | Sell: 289 369 |
Wolumen Korelacja
Seres Therapeutics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
RRGB | 0.897 |
FRSH | 0.892 |
WSBF | 0.888 |
EVCM | 0.884 |
SVC | 0.882 |
RDUS | 0.881 |
ALHC | 0.879 |
DMTK | 0.877 |
TWKS | 0.876 |
LPSN | 0.871 |
10 Najbardziej negatywne korelacje | |
---|---|
KINS | -0.881 |
EDAP | -0.88 |
FBIOP | -0.88 |
XLRN | -0.876 |
RETA | -0.873 |
JUPW | -0.87 |
RDNT | -0.865 |
CRDF | -0.864 |
LAB | -0.864 |
ACGL | -0.864 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Seres Therapeutics Inc Korelacja - Waluta/Towar
Seres Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $126.33M |
Zysk brutto: | $111.21M (88.04 %) |
EPS: | $-0.890 |
FY | 2023 |
Przychody: | $126.33M |
Zysk brutto: | $111.21M (88.04 %) |
EPS: | $-0.890 |
FY | 2022 |
Przychody: | $7.13M |
Zysk brutto: | $6.12M (85.91 %) |
EPS: | $-2.35 |
FY | 2021 |
Przychody: | $144.93M |
Zysk brutto: | $144.93M (100.00 %) |
EPS: | $-0.720 |
Financial Reports:
No articles found.
Seres Therapeutics Inc
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej